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ABSTRACT
Objectives: This study assesses satisfaction with iron chelation therapy
(ICT) based on a reliable and valid instrument, and explores the relation-
ship between satisfaction and adherence to ICT.
Methods: Patients in the USA and UK completed a new “Satisfaction with
ICT” (SICT) instrument consisting of 28 items, three pertaining to adher-
ence. Simple and multivariate regression analyses assessed the relationship
between satisfaction with different aspects of ICT and adherence.
Results: First assessments of the SICT instrument indicate its validity and
reliability. Recommended thresholds for internal consistency, convergent
validity, discriminant validity, and ﬂoor and ceiling effects were met. A
number of variables were identiﬁed in the simple linear regression analyses
as signiﬁcant predictors of “never thinking about stopping ICT,” a proxy
for adherence. These signiﬁcant variables were entered into themultivariate
model to assess the combined factor effects, explaining 42% of the total
variance of “never thinking about stopping ICT.” A signiﬁcant and positive
relationship was demonstrated between “never thinking about stopping
ICT” and age (P = 0.04), Perceived Effectiveness of ICT (P = 0.003), low
Burden of ICT (P = 0.002), and low Side Effects of ICT (P = 0.01).
Conclusions: The SICT is a reliable and valid instrument which will be
useful in ICT clinical trials. Furthermore, the administration of ICT by
slow subcutaneous infusion negatively impacts on satisfaction with ICT
which was shown to be a determinant of adherence. This points to the
need for new more convenient and less burdensome oral iron chelators to
increase adherence, and ultimately to improve patient outcomes.
Keywords: adherence, instrument, iron chelation therapy, oral adminis-
tration, satisfaction, SICT, subcutaneous administration.
Introduction
Approximately 900,000 individuals worldwide are expected to
be born with thalassemia over the next 20 years [1]. Further-
more, about 250,000 individuals worldwide are diagnosed with
sickle cell disease (SCD) per year [2], and myelodysplastic syn-
drome (MDS) is primarily manifested in older individuals with
20 to 50 out of 100,000 individuals per year diagnosed over the
age of 60 years [3].
Blood transfusions are an essential part of therapy in the
treatment of many patients with thalassemia, SCD, and MDS.
One consequence of regular blood transfusions is excess iron
intake, which cannot be excreted naturally from the body,
and accumulates (hemosiderins) in insoluble ferritin complexes
deposited mainly in the liver, spleen, a number of endocrine
organs, and the myocardium. This leads to tissue damage and
ﬁbrosis [4,5]. Further, without treatment for iron overload,
patients may not survive, and cardiac complications are usually
the main cause of death.
To avoid complications of iron overload, chronically trans-
fused patients must receive life-long iron chelation therapy (ICT)
[6]. Deferoxamine or desferal (DFO) is administered via subcu-
taneous infusion at home by the patient overnight or during the
day over 8 to 12 hours, at least 5 days per week [7]. Although
DFO-related ICT has an acceptable safety proﬁle, the treatment
regimen is not only time-consuming but burdensome to patients
[7], and negatively impacts on their health-related quality of life
(HRQoL) [8].
In one study, univariate analysis found that the degree of
discomfort with DFO-related ICT and ferritin level signiﬁcantly
inﬂuenced patients’ perceptions of their HRQoL, and the risk
of a low HRQoL score increased with the degree of discomfort
[9]. Another study in Malaysia explored HRQoL in children
with thalassaemia compared to healthy controls using the
23-item Pediatric Quality of Life Inventory (PedsQL 4.0
Generic Core Scales), and revealed that patients with thalas-
semia receiving DFO via blood transfusions have a lower
HRQoL compared to healthy controls regardless of age, sex,
ethnicity, and household income [10]. Furthermore, in a US
study cohort of patients receiving DFO, HRQoL was compro-
mised in patients receiving DFO. The differences between the
Short Form 36-Item Health Survey (SF-36) domain scores and
age-matched norms were often of the magnitude of at least 3 to
5 units, which indicates that these results were clinically mean-
ingful and signiﬁcant [11]. In other studies, the HRQoL
domains affected by DFO-related ICT include: depression,
fatigue, dyspnoea, physical functioning, psychological distress,
general health, and decrease in HRQoL during hospitalization
[11–13].
Further, local injection site reactions that are generally not
serious but bothersome to patients include: bumps, rashes and
bruises, and infections [14,15]. Patients on DFO-related ICT may
experience other side effects such as: neutropenia, hematological
toxicity, shortness of breath, headaches, and dizziness [16].
Given the signiﬁcant negative impact of DFO-related ICT on
patients’ HRQoL, and the potential side effects experienced, it is
perhaps not surprising that many patients do not adhere to their
DFO regimen as recommended by their doctors [17–20], and it is
estimated that up to 50% of patients in the UK may not fully
adhere to their DFO-related ICT regimen [21].
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Less demanding to adhere to is the oral chelator deferasirox
(Exjade Novartis Pharma Stein AG, Stein, Switzerland) [22,23].
In some countries (although not in the USA or Canada), defer-
iprone (Ferriprox Apotex, Inc., Weston, ON, Canada) is an
approved alternative oral chelator with various restrictions on
the label. In patients with thalassemia, it has been shown to be
less effective at lowering hepatic iron than subcutaneous DFO
[24,25].
There is an expanding body of evidence in patients with
thalassemia and SCD that suggests increased satisfaction with
ICT would reduce the likelihood of patients stopping their treat-
ment [26,27]. Consequently, patient satisfaction with ICT is an
important patient outcome and should be considered during
patients’ overall treatment management.
While some research indicates that satisfaction with treat-
ment and care is associated with factors such as age, dosage, and
side effects [28], to our knowledge, there are no studies which
considered all the factors associated with satisfaction with ICT,
nor any adequate instrument available to reliably quantify the
concept [8]. This ﬁnding supports the assertion of Linder-Pelz
(1982) that there is very little satisfaction research that tests or
builds on theory, and which provides data to explain the asso-
ciation between satisfaction with treatment and patient behav-
iors such as adherence [29].
The objectives of this article are threefold. Speciﬁcally to: 1)
describe the development scoring, and validity of the Satisfaction
with ICT instrument (SICT) instrument; 2) report satisfaction
results of a binational, multicenter, retrospective chart review,
and semiprospective study in the USA and UK; and 3) investigate
based on empirical ﬁndings the relationship between satisfaction
and adherence of ICT.
Patients and Methods
Study Design and Patient Population
As part of a retrospective chart review and semiprospective inves-
tigation [11], patients with thalassaemia, SCD, orMDS from eight
study sites (four per country: USA and UK) completed the SICT
instrument at one study visit. Study protocols and questionnaires
were reviewed by an ethics committee and approval was ob-
tained by the investigator at each participating center.
Patient eligibility was veriﬁed by the principal investigator.
The inclusion criteria were: 1) females or males 6 years of age;
with 2) diagnosis of thalassaemia, SCD, or MDS; 3) minimum of
3 months of ongoing ICT at the time of study enrolment; and 4)
provided written informed consent. Exclusion criteria were: 1)
patients at the study site for less than 6 months before ﬁrst study
visit; 2) those less than 18 years of age without (available) car-
egiver; or 3) patient was deemed too unwell as a result of comor-
bid medical conditions.
Because there is no formal method to establish sample size to
conduct exploratory factor analysis, the generally accepted rule
of ﬁve to 10 participants for every item was employed [30]. With
26 items to be included in the factor analysis (two items were not
included because their answer choice was not an ordinal scale), it
was estimated that 130 patients was a sufﬁcient sample size.
Nevertheless, because of the low prevalence of such disorders
[2,3], a lower number of patients was considered acceptable.
SICT Instrument
A 28-item SICT instrument was developed based on a literature
review, patient interviews, clinician interviews, item generation,
and face and content validity testing.
The ﬁrst draft of the instrument was created based on the
results of three expert clinician interviews, and four patient inter-
views (two thalassaemia, one SCD, and one MDS patient). A
further nine patient interviews (four thalassaemia, one SCD, and
four MDS patients) were conducted. The open-ended questions
ensured all relevant concepts were covered and cognitive debrief-
ing ensured patient understanding of the instrument. The 28-item
SICT instrument included an assessment of satisfaction with prior
experiencewith ICT, adherence to treatment, and preferences. The
majority of items were measured on a 5-point Likert scale, where
1 represented “always” and 5 “never,” or 1 being “very satisﬁed”
and 5 “very dissatisﬁed.” This scale allows for non–forced-choice
answers so that respondents could answer neutrally [31]. Further-
more, Likert scales are more valid than forced-choice scales,
reduce consenting response bias, and are therefore very reliable
[32]. Multiitem scale scores were calculated as the mean of the
items if at least half of the items within a scale were completed.
Based on the literature searches, three expert interviews, and
13 patient interviews, it was hypothesized that the newly devel-
oped instrument should have eight domains: satisfaction with
ICT effectiveness, safety/side effects, convenience of ICT, costs,
overall satisfaction, ICT impact on daily life, patient adherence,
and ICT preferences.
Patient-Reported Outcome Measures
Participants also completed four well-established HRQoL mea-
sures to assess the concurrent validity of the daily life domain of
the SICT instrument (how well concepts are measured). These
were SF-36 [33], the Child Health Questionnaire (CHQ)
[50-item parent form, for parents of children 5–17 years of age
(CHQ-PF50) or the 87-item child form, for children of 10 years
and older, (CHQ-CF87)] [34], and the Medical Outcomes Study
(MOS)-Sleep Scale (12-item questionnaire) [35].
Statistical Procedures
Descriptive and psychometric analyses were performed on the
SICT. Although PRO data are frequently nonnormal, parametric
statistical methods were used because they are robust to nonnor-
mality. Speciﬁcally, Principal Component Analysis (PCA) was
used as a type of exploratory factor analysis using orthogonal
(varimax) rotation to make sense of the complex factors associ-
ated with satisfaction, and to observe relationships between
items of the SICT instrument.
Multitrait analysis was conducted to establish the item con-
vergent validity, item discriminant validity, and internal consis-
tency (Cronbach’s Alpha 0.7). Pearson correlations between
the SICT instrument and well-established HRQoL measures were
conducted to test for the concurrent validity.
Simple linear regressions were performed to examine rela-
tionships with the SICT instrument domains and adherence as
deﬁned by “never thinking about stopping ICT.” A Multiple
Linear Regression with backward selection of the variables was
also conducted (variables were retained at P  0.05) to assess the
combined effects of the principal components of SICT in predict-
ing adherence. All tests were two-tailed, with statistical signiﬁ-
cance level of P < 0.05.
All data were analyzed using Statistical Analysis System (SAS)
version 9, or Multi-trait Analysis Program-Revised (MAP-R)
version 1.
Results
Demographics and Clinical Characteristics
Demographic data are presented in Table 1 for the total cross-
sectional sample (USA and UK). In total, 107 patients with
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thalassaemia, SCD, or MDS, currently undergoing ICT, partici-
pated in the binational study (USA: thalassaemia n = 41 and SCD
n = 8; UK: thalassaemia n = 39, SCD n = 13, and MDS n = 6).
The majority of the sample were female (58.9%, n = 63), and
the mean age was 31.5 years (range 10–85 years). Speciﬁcally,
86.9% (n = 93) were adults (over 18 years), 13.1% (n = 14)
adolescents (10–18 years).
Overall, 70.9% of patients were currently receiving DFO-
related ICT (n = 78), 17.2% on deferiprone (n = 19), and 11.8%
on combined therapy (n = 13).
United States and UK demographic details were broadly com-
parable. Nevertheless, the majority of patients in the USA (98%,
n = 48) were on DFO-related ICT with only one patient on
combination of oral and DFO-related ICT, whereas in the UK,
46.6% (n = 27) patients were on DFO-related ICT, 31% (n = 18)
were on oral ICT, and 22.4% (n = 13) were on combination ICT.
Psychometric Characteristics of the SICT Instrument
Item review and reduction. The PCA and multitrait analysis
were performed to explore the structure of the 26-item question-
naire from complete patient responses (n = 92). Items 17 and 28
were excluded from the PCA because the answer choices were
not an ordinal scale; thus, these were analyzed separately.
A four-dimensional structure was indicated by the PCA and
conﬁrmed by the multitrait analysis. Seven items were ex-
cluded from the four-dimensional structure and were analyzed
separately:
• Items 26 and 27 related to previous experience and inten-
tion and failed to correlate to any of the identiﬁed dimen-
sions.
• Items 5 and 24 were deleted because they did not meet
minimal criteria for convergent validity and failed to load
on a factor:
• Item 5: In general in the last 4 weeks, how often did
you feel worried that you were not receiving an
adequate dose of medication?
• Item 24: Overall, how did the side effects of chelation
therapy meet your expectations?
• Items 14 to 16 were adherence items:
• Item 14: In general in the last 4 weeks, how often did
you have trouble remembering to take your chelation
therapy?
• Item 15: In general in the last 4 weeks, how often did
you think about stopping your chelation therapy?
• Item 16: In general in the last 4 weeks, how often did
you follow the chelation therapy regimen exactly as
recommended by your doctor?
The ﬁnal PCA was conducted on the 19 SICT items, yielding
to four domain scores. The rotated factor pattern for the varimax
PCA is presented in Table 2. The ﬁrst four factors (domains)
represented 63% of the variability of the items.
The ﬁrst satisfaction factor or domain was labeled “Perceived
Effectiveness of ICT” and consisted of six items [1–4,13,20],
pertaining to patient perceptions regarding the beneﬁcial
outcome of ICT, and rotated factor coefﬁcients ranged from 0.64
to 0.85.
The second factor or domain, “Burden of ICT,” included ﬁve
items [6–9,19] with rotated factor coefﬁcients ranging from 0.66
to 0.77. The items related to this factor measure the negative
impact incurred from ICT on activities of daily living, sleep, time
to take ICT, and dependency.
Five items [18,21–23,25] loaded on the third factor labeled
“Acceptance of ICT” with rotated factor coefﬁcients ranging
from 0.66 to 0.75. The items deﬁning this factor reﬂect positive
orientations toward ICT with regard to expectations and conve-
nience of taking ICT.
The fourth factor or domain labeled “Side Effects of ICT”
consisted of three items [10–12] with rotated factor coefﬁcients
ranging from 0.70 to 0.84. The items pertaining to this factor
assess the potential unwanted side effects of ICT and their impact
on the individual’s appearance.
Item convergent and discriminant validity. The SICT met an
acceptable threshold for item-discriminant validity and all 19
items met the minimum threshold for item-convergent validity
(>0.4). Item-scale correlations ranged from 0.43 to 0.76, dem-
onstrating homogeneity within each domain:
Table 1 Demographic and clinical characteristics for total, USA, and UK samples
Demographic and
clinical characteristics
Cross-sectional
(N = 107)
USA sample
(N = 49)
UK sample
(N = 58)
Gender
Male n (%) 44 (41.12) 24 (48.98) 20 (34.48)
Female n (%) 63 (58.88) 25 (51.02) 38 (65.52)
Employment
Full-time n (%) 35 (32.71) 19 (38.78) 16 (27.59)
Part-time n (%) 16 (14.95) 9 (18.37) 7 (12.07)
Unemployed n (%) 50 (46.73) 21 (42.86) 29 (50.00)
Retired n (%) 6 (5.61) 0 (0.00) 6 (10.34)
Age (years) Mean (SD) 31.51 (14.65) 28.54 (9.60) 34.01 (17.54)
Patient disease
Thalassaemia n (%) 80 (74.77) 41 (83.67) 39 (67.24)
SCD n (%) 21 (19.63) 8 (16.33) 13 (22.41)
MDS n (%) 6 (5.61) 0 (0.00) 6 (10.34)
Ferritin levels (mg/L)
Mean level of ferritin in the most recent year Mean (SD) 2888 (2247) 2750 (2505) 3006 (2015)
Number of side effects in the previous year
0 n (%) 79 (73.83) 37 (75.51) 42 (72.41)
1 n (%) 18 (16.82) 8 (16.33) 10 (17.24)
2 and above n (%) 10 (9.35) 4 (8.16) 6 (10.34)
Number of doses/week patients are suppose to take
1 to 5 n (%) 59 (55.14) 36 (73.47) 23 (39.66)
6 and above n (%) 48 (44.86) 13 (26.53) 35 (60.34)
SCD, sickle cell disease; MDS, myelodysplastic syndrome.
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• Satisfaction with Perceived Effectiveness of ICT: 0.51 to
0.76;
• Acceptance of ICT: 0.43 to 0.74;
• Burden of ICT: 0.51 to 0.68;
• Side Effects of ICT: 0.63 to 0.71.
Internal consistency. Internal consistency for all subscales was
good, with alpha coefﬁcients meeting the minimum recom-
mended threshold >0.7: Satisfaction with Perceived Effectiveness
of ICT 0.86, Acceptance of ICT 0.80, Burden of ICT 0.82, and
Side Effects of ICT 0.81.
Concurrent validity. In general, the Burden domain of the SICT
instrument indicated low to moderate correlations with HRQoL
measures: SF-36: r = 0.29 to 0.45, n = 93; CHQ-PF50: r = 0.00
to 0.33, n = 14; CHQ-CF87: r = 0.03 to 0.78, n = 14; and MOS-
Sleep Scale r = -0.02 to 0.36, n = 93 (Table 3).
Correlations between each of the SICT domains compared to
the other domains of the SICT are also presented in Table 3.
Description of Satisfaction Scores by treatment group.
Because a score of 5 represents “very satisﬁed” for all items in a
domain, a mean of 3.5 or more suggests that most patients were
satisﬁed or very satisﬁed with most or all of the items in the
domain. Figure 1 shows satisfaction results by type of treatment.
Closer observation shows that patients treated with oral ICT
were more satisﬁed with acceptance, burden, and side effects of
ICT compared to patients treated by DFO-related ICT or a
combination of DFO-related and oral ICT. Indeed, the type of
treatment had a statistically signiﬁcant effect on the satisfaction
scores (P(SE) = 0.0010; P(AC) < 0.0001; P(BD) = 0.0004).
Discriminant validity. Statistically signiﬁcant differences in mean
satisfaction scores were observed between: patients who experi-
ence side effects and those who did not (P < 0.001 for all scales)
and patients whose number of doses per week were 5
and those with >5 doses (Acceptance of ICT: x¯ = 2.70 and
x¯ = 3.45, P = 0.001; Burden of ICT: x¯ = 3.41 and x¯ = 3.82,
P = 0.03; Side Effects of ICT: x¯ = 2.77 and x¯ = 3.46, P = 0.002)
(Table 4).
There were no statistically signiﬁcant differences in mean
SICT scores for any domains for the following variables: age,
sex, and mean ferritin levels.
Predictors of adherence. Demographics and clinical characteris-
tics, as well as SICT domains, were explored as potential predic-
tors of adherence (deﬁned by never thinking about stopping ICT)
(Table 5). Simple regression analyses showed that of 18 variables
tested, 10 signiﬁcantly predicted adherence. Patient disease
(thalassemia, SCD or MDS) explained the most variance associ-
ated with never thinking about stopping chelating therapy
(r2 = 31.7%, P < 0.0001), followed by Burden of ICT (r2 =
29.7%,P < 0.0001), Side Effects of ICT (r2 = 26.0%,P < 0.0001),
Acceptance of ICT (r2 = 15.5% P < 0.0001), age (r2 = 10.8%,
P = 0.0005), full-time employment (r2 = 10.2%, P = 0.0008),
Satisfaction with Perceived Effectiveness of ICT (r2 = 9.3%,
P = 0.0014), unemployment (r2 = 5.5%, P = 0.0151), and
number of doses missed in the last 7 days (r2 = 5.2%, P = 0.019).
Table 2 A factor loading matrix, using varimax-rotated principal components, based on 19 items of the SICT instrument*
Rotated factor pattern
Perceived
Effectiveness Burden Acceptance
Side
Effects
Item 1 Your current chelation therapy would help you live longer? 0.852 0.015 0.090 -0.063
Item 3 Your chelation therapy would stop the iron overload from getting worse? 0.851 0.039 -0.028 0.028
Item 2 Your chelation therapy would get rid of the iron overload? 0.850 0.006 -0.003 0.048
Item 4 Your chelation therapy was working? 0.713 0.129 0.252 -0.174
Item 20 Overall, how worthwhile was your chelation therapy? 0.640 -0.209 0.106 -0.027
Item 13 That chelation therapy was worth taking/having? 0.636 -0.072 0.0001 -0.059
Item 9 That chelation therapy made you dependent on others? -0.028 0.766 0.049 0.114
Item 8 That your chelation therapy regimen stopped you from getting a good night
sleep?
-0.017 0.741 -0.124 0.337
Item 19 Overall, how bothered were you by the amount of time it took to take your
chelation therapy?
-0.146 0.675 -0.355 0.217
Item 6 That your chelation therapy regimen limited your evening or night time
activities?
0.021 0.666 -0.264 0.338
Item 7 That your chelation therapy regimen limited your daytime activities? 0.017 0.655 -0.159 0.090
Item 22 How easy or difﬁcult was it to take chelation therapy? 0.032 -0.419 0.754 -0.209
Item 18 Overall, how convenient or inconvenient was it for you to take your chelation
therapy?
-0.038 -0.236 0.721 -0.103
Item 25 Overall, how satisﬁed or dissatisﬁed were you with the form of your chelation
therapy (oral pill/capsules or pump)?
-0.006 -0.052 0.717 -0.194
Item 23 Overall, how well did the beneﬁts of chelation therapy meet your
expectations?
0.255 -0.024 0.665 0.243
Item 21 Was chelation therapy as difﬁcult as you expected it would be? -0.200 0.098 -0.661 0.353
Item 11 Upset about the side effects of your chelation therapy (e.g., pain)? -0.064 0.284 -0.034 0.841
Item 12 That chelation therapy negatively affected the appearance of your body or
skin?
-0.046 0.270 -0.154 0.754
Item 10 Pain because of your chelation therapy? -0.091 0.322 -0.315 0.701
*Eigenvalues and cumulative variance:
Factor Eigenvalue Cumulative
Perceived Effectiveness 6.249 0.240
Burden 3.603 0.379
Acceptance 2.214 0.464
Side Effects 1.418 0.519
SICT, satisfaction with iron chelation therapy. Bold items correspond to the appropriate SICT domain.
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Multivariate regression analysis was conducted based on
independent variables that signiﬁcantly predicted never thinking
about stopping ICT. Four independent variables signiﬁcantly pre-
dicted never thinking about stopping ICT (r2 = 42.3%): age
(P = 0.04), Perceived Effectiveness of ICT (P = 0.003), low
Burden of ICT (P = 0.002), and low Side Effects of ICT
(P = 0.01).
Discussion
The study objectives were to: 1) describe the development,
scoring, and validity of the SICT instrument; 2) report satisfac-
tion results of a binational, multicenter, retrospective, and semi-
prospective study in the USA and UK; and 3) investigate the
relationship between satisfaction and adherence of ICT.
The PCA revealed four domains based on 19 items (Satisfac-
tion with Perceived Effectiveness of ICT, Acceptance of ICT,
Burden of ICT, and Side Effects of ICT) accounting for 63% of the
systematic covariance of the satisfaction items. Seven items were
not included in the four-dimensional structure and were analyzed
separately: two nonordered items assessing reasons for not taking
chelation therapy as directed and preference for type of chelation
therapy; three items related to adherence; and two items related to
the previous experience of the patients. Nevertheless, the items “In
general, in the past 4 weeks, how often did you feel worried you
were not receiving an adequate dose of medication?” and
“Overall, howdid the side effects of ICTmeet your expectations?”
did not load on any of the factors and were deleted from the
questionnaire. Further research is warranted to conﬁrm with
greater certainty the factor structure of the SICT instrument.
Table 3 Correlations between SICT domains and HRQoL domains and summary scores
Perceived effectiveness
with ICT Acceptance of ICT Burden of ICT Side effects of ICT
SF-36 Physical Functioning 0.193 0.143 0.355* 0.248*
SF-36 Role physical 0.090 0.2 0.294* 0.187
SF-36 Pain index 0.168 0.225 0.446* 0.336*
SF-36 General Health perceptions 0.225* 0.218* 0.285* 0.310*
SF-36 Vitality 0.064 0.174 0.370* 0.233*
SF-36 Social Functioning 0.237* 0.191 0.419** 0.346*
SF-36 Role Emotional 0.130 0.164 0.327* 0.214*
SF-36 Mental Health Index 0.174 0.157 0.314* 0.398*
SF-36 Health Transition Index 0.08 -0.142 -0.028 -0.007
SF-36 Physical Component Summary Score 0.166 0.201 0.352 0.238*
SF-36 Mental Component Summary 0.155 0.167 0.350* 0.338*
SF-6D Utility Score 0.206* 0.194 0.364* 0.334*
CHQ-PF50 Global Behaviour 0.140 0.206 -0.272 0.110
CHQ-PF50 Family Cohesion -0.040 0.235 -0.300 0.118
CHQ-PF50 Physical Functioning -0.018 0.211 0.329 0.570*
CHQ-PF50 Role Emotional/behaviour -0.198 0.380 0.217 0.418
CHQ-PF50 Role physical -0.055 0.369 0.000 0.265
CHQ-PF50 Bodily Pain 0.197 0.424 0.334 0.335
CHQ-PF50 Behaviour 0.052 0.253 -0.121 0.220
CHQ-PF50 Mental Health 0.013 0.094 -0.40 0.224
CHQ-PF50 Self Esteem -0.022 0.416 0.143 0.561
CHQ-PF50 General Health -0.039 0.082 0.311 -0.174
CHQ-PF50 Parent Impact Emotional 0.025 0.403 0.03 0.321
CHQ-PF50 Parent Time Impact 0.026 0.396 0.129 0.585*
CHQ-PF50 Family Activities 0.103 0.330 0.057 0.487
CHQ-PF50 Physical Summary Score 0.009 0.434 0.265 0.496
CHQ-PF50 Psychosocial Summary Score -0.020 0.346 -0.056 0.402
CHQ-CF87 General Health 0.608* 0.515 0.029 0.345
CHQ-CF87 Global Behaviour 0.251 0.412 0.331 0.250
CHQ-CF87 Family Cohesion 0.357 -0.017 0.061 -0.197
CHQ-CF87 Physical Functioning 0.146 0.228 0.277 0.298
CHQ-CF87 Role Functioning Emotional 0.314 0.548* 0.290 0.369
CHQ-CF87 Role Functioning Behaviour 0.054 0.322 -0.050 0.121
CHQ-CF87 Role Functioning Physical 0.259 0.512 0.401 0.419
CHQ-CF87 Bodily Pain 0.227 0.497 0.275 0.297
CHQ-CF87 Behaviour 0.355 0.192 -0.171 -0.037
CHQ-CF87 Mental Health 0.352 0.404 0.249 0.323
CHQ-CF87 Self-Esteem Scale 0.166 0.327 0.180 0.231
CHQ-CF87 General Health Scale 0.552* 0.768* 0.782* 0.611*
CHQ-CF87 Family Activities 0.481 0.431 0.640* 0.453
MOS-Sleep Quantity of Sleep -0.03 0.072 0.028 -0.030
MOS-Sleep Disturbance -0.169 -0.207* -0.314 -0.275
MOS-Sleep Snoring 0.01 -0.062 -0.019 -0.035
MOS-Sleep Adequacy 0.239* 0.128 0.272* 0.144
MOS-Sleep Somnolence -0.397** -0.057 -0.236* -0.156
MOS-Sleep Problem Index (6 items) -0.235* -0.117 -0.345* -0.266*
MOS-Sleep Problem Index (9 items) -0.256* -0.169 -0.357* -0.264*
SICT Perceived Effectiveness with ICT — 0.20 0.09 0.14
SICT Acceptance of ICT 0.20 — 0.48 0.43
SICT Burden of ICT 0.09 0.48 — 0.62
SICT Side Effects of ICT 0.14 0.43 0.62 —
*P < 0.05; **P < 0.0001.
SICT, satisfaction with iron chelation therapy; HRQoL, health-related quality of life; SF-36, Short Form 36-Item Health Survey;MOS,Medical Outcomes Study; CHQ,Child Health Questionnaire;
—, not applicable. Bold numbers indicate signiﬁcant correlations.
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All four domains of the SICT instrument had satisfactory
internal consistency reliability, exceeding Nunnally’s threshold
of 0.70 [36]. Although there were low to moderate correlations
between the Burden domain of the SICT and HRQoL mea-
sures, future research could better assess the concurrent validity
of the SICT by observing correlations with the generic Treat-
ment Satisfaction Questionnaire for Medication [37].
The second objective was to report the satisfaction results of
this binational, multicenter, retrospective, and semiprospective
study in the USA and UK.
Overall, mean satisfaction scores revealed that the majority of
scores were positive. Closer observation revealed that orally
treated patients were more satisﬁed with acceptance, burden, and
side effects of ICT compared to patients treated by DFO-related
or a combination of DFO-related ICT and oral ICT.
This ﬁnding is supported by previous research which indi-
cates that DFO-related ICT is often burdensome to patients and
negatively impacts on patient’s HRQoL [8,10,11,20]. These ﬁnd-
ings can be used as a benchmark for future studies although
further research is necessary on this subject.
The third objective of this article was to describe, based on
empirical ﬁndings, the relationship between satisfaction with ICT
and adherence. Results indicated that satisfaction with ICT (spe-
ciﬁcally satisfaction with: perceived effectiveness, burden, and
side effects) and age are signiﬁcant predictors of “never thinking
about stopping ICT” (Fig. 2). These ﬁndings were in line with
previous research [26,27], explaining 42% of the total adherence
variance. This ﬁnding is signiﬁcant because to our knowledge,
few studies have explored the association of satisfaction and
adherence to ICT regimens. Nevertheless, the remaining 58% of
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Figure 1 Mean satisfaction scores and standard
deviations for overall cross-sectional data per type
of treatment.AC,Acceptance of ICT; BD, Burden of
ICT; PE, Perceived Effectiveness; SE, Side Effects of
ICT.
Table 4 Means and standard deviations of the SICT domains
Characteristic n
Perceived
Effectiveness of ICT
Acceptance
of ICT
Burden
of ICT
Side Effects
of ICT
Mean SD Mean SD Mean SD Mean SD
Gender
Male 44 4.37 0.58 3.12 0.75 3.70 0.94 3.34 1.13
Female 63 4.33 0.74 2.98 0.92 3.52 1.02 2.90 1.15
Age group
Adolescents 14 4.20 0.58 3.04 0.72 3.20 1.11 2.64 1.24
Adults 93 4.37 0.69 3.04 0.87 3.65 0.96 3.15 1.14
Employment
Full-time 35 4.58 0.46 3.07 0.81 3.91 0.75 3.53 0.92
Unemployed 50 4.28 0.70 3.04 0.89 3.32 1.03 2.77 1.20
Country
UK 58 4.36 0.66 3.28 0.96 3.52 1.09 3.14 1.27
USA 49 4.34 0.71 2.75 0.60 3.68 0.85 3.01 1.01
Any side effects in the
previous 30 days
No 46 4.39 0.69 3.42 0.95 4.03 0.92 3.69 1.18
Yes 61 4.32 0.67 2.75 0.64 3.27 0.91 2.62 0.91
Number of doses per week that
patient is supposed to take
5 59 4.38 0.65 2.70 0.58 3.41 0.93 2.77 1.09
>5 48 4.31 0.71 3.45 0.95 3.82 1.01 3.46 1.13
Mean level of ferritin in most
recent year
Data missing 1 4.67 — 2.60 — 1.60 — 1.33 —
1500 39 4.33 0.81 3.06 0.81 3.72 0.96 3.15 1.03
1500–3000 28 4.38 0.57 3.04 0.80 3.46 1.05 3.11 1.17
>3000 39 4.33 0.63 3.03 0.95 3.62 0.94 3.04 1.28
SICT, satisfaction with iron chelation therapy.
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unexplained variance suggests that apart from age and satisfac-
tion with ICT, there may be other factors that have signiﬁcant
importance in explaining adherence to ICT. For example, an
international survey exploring views of patients receiving DFO-
related ICT revealed that the level of support received from
specialist organizations may directly inﬂuence patient adherence
to ICT [17]. In another study, a sharing of responsibilities for ICT
between both parents and children with SCD was associated with
a higher level of adherence, as was low family stress although
home care regimens and convenience were not reported as useful
predictors of adherence. It is possible, however, that treatment
location is important for adult patients and this may have
accounted for some of the differences in satisfaction with the pill
versus infusion modalities [38].
Alternatively, a possible explanation for the unexplained vari-
ance in this study is that the study design may have impacted on
the ability to determine signiﬁcant predictors of adherence—
because cross-sectional designs are limited in determining cause
and effect relationships, and there is potential for confounding
variables [39].
Table 5 Description of the relationship between adherence of ICT (never think about stopping ICT) and its predictors
Description of the relationship
with adherence*
Simple regression analysis
r2 (%) P-value
Patient disease MDS: 4.33
SCD: 2.38
Thal: 4.19
31.7 <0.0001
Satisfaction with Burden of ICT 0.55 29.7 <0.0001
Satisfaction with Side Effects of ICT 0.51 26.0 <0.0001
Satisfaction with Acceptance of ICT 0.39 15.5 <0.0001
Age 0.33 10.8 0.0005
Full-time No: 3.56
Yes: 4.43
10.2 0.0008
Satisfaction with Perceived Effectiveness of ICT 0.31 9.3 0.0014
Unemployed No: 4.12
Yes: 3.52
5.5 0.0151
Number of doses missed in the past 7 days -0.23 5.2 0.0185
Experience of side effects No: 4.13
Yes: 3.62
3.8 0.0433
*Pearson correlation coefﬁcients for continuous predictors; mean adherence score per subgroups for categorical predictors.
ICT, iron chelation therapy; MDS, myelodysplastic syndrome; SCD, sickle cell disease;Thal, thalassemia.
p=0.003 
Satisfaction with 
Perceived 
Effectiveness of ICT
Satisfaction with 
Burden of ICT
Adherence
r2=42% 
Age
p=0.01 
p=0.04 
Satisfaction with Side 
Effects of ICT
p=0.002 
Multivariate linear regression showed that there were no significant associations between never thinking about stopping chelation therapy 
(adherence) and the following independent variables: employment; presence of side effects; feelings about you; and satisfaction with acceptance 
0.44
0.42
0.27
0.01
Figure 2 A supported conceptual framework of satisfaction with ICT in patients with iron overload. ICT, iron chelation therapy.
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This study extends previous research efforts to include aspects
perceived important by both patients and health professionals, to
develop an instrument to quantify satisfaction with ICT. The
utility of this instrument might be directed to other clinical trials
which assess satisfaction with ICT or a short form of the scale
might be used in routine clinical practice to assess aspects of ICT
relevant to patient satisfaction. This would allow clinicians to
acknowledge, target, and improve aspects of ICT that patients
are perhaps dissatisﬁed with (e.g., side effects), therefore manag-
ing patients’ medication programs more effectively as well as
improving and maintaining patient well-being. Nevertheless, the
usage of a shorter form of the scale for clinical practice would
require further psychometric validation. The SICT could be used
to provide an indication of best practice and could provide a
point of reference for future research and development in clinical
practice.
Conclusions
In conclusion, the initial psychometric analyses of the SICT
instrument suggest that it is a reliable and valid instrument.
Further validation is required to assess its test–retest reliability
and responsiveness. The satisfaction results from the study
reported here indicated that DFO-related ICT negatively impacts
satisfaction and that SICT is a determinant of adherence. This
points to the need for a new, more convenient, and less burden-
some oral iron chelators, which will increase adherence and
ultimately to improve patient outcomes.
Source of ﬁnancial support: Novartis has commissioned Mapi Values to
advise on patient reported outcome strategies for their clinical trials.
References
1 Vichinsky EP. Changing patterns of thalassemia worldwide. Ann
N Y Acad Sci 2005;1054:18–24.
2 Serjeant GR. Sickle-cell disease. Lancet 1997;350:725–30.
3 Cazzola M, Malcovati L. Myelodysplastic syndromes—coping
with ineffective hematopoiesis. N Engl J Med 2005;352:536–
8.
4 Olivieri NF, Brittenham GM. Iron-chelating therapy and the
treatment of thalassemia. Blood 1997;89:739–61.
5 Harvard Medical School. Effects of iron overload: hemochroma-
tosis, tranfusional iron overload. Available from: http://
sickle.bwh.harvard.edu/index.html [Accessed August, 2006].
6 Gabutti V, Piga A. Results of long-term iron-chelating therapy.
Acta Haematologica 1996;91:26–36.
7 Vidler V. Compliance with iron chelation therapy in beta thalas-
saemia. Paediatr Nurs 1998;10:17–8.
8 Abetz L, Baladi JF, Jones P, Rofail D. The Impact of iron overload
and its treatment on quality of life: results from a literature
review. Health Qual Life Outcomes 2006;4:73.
9 Arboretti R, Tognoni G, Alberti D, and Italian Colaborative
Group on Thalassaemia. Pharmacosurveillance and quality of
care of thalassaemic patients. A large scale epidemiological
survey. Eur J Clin Pharmacol 2001;56:915–22.
10 Ismail A, Campbell MJ, Ibrahim HS, Jones GL. Health related
quality of life in Malaysian children with thalassaemia. Health
Qual Life Outcomes 2006;4:39.
11 Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic
burden of infused iron chelation therapy (ICT) in the United
States. Transfusion 2007;47:1820–9.
12 Kornblith AB, Herndon JE, Silverman LR, et al. Impact of aza-
cytidine on the quality of life of patients with myelodysplastic
syndrome treated in a randomized phase III trial: a cancer and
leukemia group B study. J Clin Oncol 2002;20:2441–52.
13 Hasan SP, Hashmi S, Alhassen M, et al. Depression in sickle cell
disease. J Natl Med Assoc 2003;95:533–7.
14 Rebulla P. Transfusion reactions in thalassemia. A survey from
the Cooleycare programme. The cooleycare cooperative group.
Haematologica 1990;75(Suppl. 5):S122–7.
15 Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia:
an optimistic update. Semin Hematol 2001;38:360–6.
16 Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and
safety of combined iron-chelation therapy with deferoxamine and
deferiprone. Hematol J 2004;5:475–9.
17 Ward A, Caro JJ, Green TC, et al. An international survey
of patients with thalassemia major and their views about sustain-
ing life-long desferrioxamine use. BMC Clin Pharmacol 2002;2:
3.
18 Caro JJ, Ward A, Green TC, et al. A. Impact of thalassemia major
on patients and their families. Acta Haematologica 2002;107:
150–7.
19 Ratip S, Skuse D, Porter J, et al. Psychosocial and clinical burden
of thalassaemia intermedia and its implications for prenatal diag-
nosis. Arch Dis Child 1995;72:408–12.
20 Atkin K, Ahmad WIU. Family caregiving and chronic illness: how
parents cope with a child with sickle cell disorder or thalassaemia.
Health Soc Care Community 2000;8:57–69.
21 Modell B, Khan M, Darlison M. Survival in beta-thalassemia
major in the UK: data from the UK thalassemia register. Lancet
2000;355:2051–2.
22 Vichinsky E, Onyekwere O, Porter J, et al. Patient reported
outcomes of deferasirox (exjade ICL670) in comparison with
deferoxamine in sickle cell disease patients with transfusional
hemosiderosis: a randomised comparative, open label phase II
Trial. Br J Haematol 2006;136:501–8.
23 Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient reported
outcomes of deferasirox (exjade, icl670) in comparison with def-
eroxamine in beta-thalassemia patients with transfusional hemo-
siderosis: a randomized comparative, open-label phase III trial. Br
J Haematol 2006;106:Abstract 2704.
24 Olivieri N, Brittenham GM, McLaren CE, et al. Long-term safety
and effectivness of iron chelation therapy with deferiprone for
thalassemia major. N Engl J Med 1998;339:417–23.
25 Caro JJ, Huybrechts K, Green TC. Estimates of the effect on
hepatic iron of oral deferiprone compared to subcutaneous des-
ferrioxamine for treatment of iron overload in thalassaemia
major: a systematic review. BMC Blood Disord 2002;2:4.
26 Rofail D, Viala M, Baladi J-F, et al. Satisfaction with ICT predicts
never thinking about stopping chelation therpay in patients with
iron overload. Ann Oncol 2006;17(Suppl. 9):ix 193. (Poster Pre-
sented at ESMO, Istanbul, Turkey).
27 Rofail D, Revera S, Scalone L, et al. Satisfaction with iron chela-
tion therapy and its impact on adherence in patients with beta
thalassemia major: results from the ITHACA study. Poster Pre-
sented at ISPOR, Florence, 2006.
28 Hall J, Dornan MC. Patient sociodemographic characteristics as
predictors of satisfaction with medicine. Soc Sci Med 1990;30:
811–8.
29 Linder-Pelz SU. Toward a theory of patient satisfaction. Soc Sci
Med 1982;16:577–82.
30 Staquet NJ, Hays RD, Fayers PN. Quality of life assessments in
clinical trials: methods and practice. Oxford: Oxford University
Press, 1998.
31 Guy RG, Norvell M. The neutral point on a likert scale. J Psychol
1977;95:199–204.
32 Ray JJ. Acquiescence and problems with forced-choice scales. J
Soc Psychol 1990;130:397–99.
33 Ware JE Jr, Sherbourne, CD. The MOS 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care 1992;30:473–83.
34 Landgraf JM, Abetz L, Ware JE. The CHQ: a user’s Manual (2nd
ed.). Boston, MA: The Health Institute, 1996.
35 Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE,
eds. Measuring Functioning and Well-being. The Medical Out-
comes Study Approach. Durham & London: Duke University
Press, 1992.
116 Rofail et al.
36 Nunnally JC. Psychometric Theory (2nd ed.). NewYork:McGraw
Hill, 1978.
37 Atkinson MJ, Kumar R, Cappelleri JC, Hass S. Hierarchical
construct validity of the treatment satisfaction questionnaire for
medication (TSQM Version II) among outpatient pharmacy con-
sumers. Value Health 2005;8(Suppl. 1):S1–60.
38 Treadwell M, Law AW, Sung J, et al. Barriers to adherence of
derferoxamine usage in sickle cell disease. Paediatr Blood Cancer
2005;44:500–7.
39 Tabachnick BG, Fidell LS. Using Multivariate Statistics (4th ed.).
Needham Heights, MA: Allyn & Bacon, 2001.
Satisfaction & Adherence in Patients on ICT 117
